REG - AstraZeneca PLC - AstraZeneca prices a $2.25bn bond offering

AstraZenecaAnnouncement

01/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230301:nRSA4227Ra&default-theme=true

RNS Number : 4227R  AstraZeneca PLC  01 March 2023

1 March 2023 07:00 GMT

 

AstraZeneca prices a $2.25bn bond offering

 

AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary
AstraZeneca Finance LLC, priced a three tranche global bond offering totalling
$2.25bn on 28 February 2023. The offering is expected to close on 3 March
2023, subject to customary closing conditions. The transaction, which is a
global offering registered with the US Securities and Exchange Commission
("SEC"), consists of the following three tranches:

Notes issued by AstraZeneca Finance LLC and fully and unconditionally
guaranteed by AstraZeneca

·    $1.1bn of fixed rate notes with a coupon of 4.875%, maturing 3 March
2028;

·    $650m of fixed rate notes with a coupon of 4.900%, maturing 3 March
2030; and

·    $500m of fixed rate notes with a coupon of 4.875%, maturing 3 March
2033.

AstraZeneca expects to use the net proceeds of the offering for general
corporate purposes, which may include the refinancing of existing
indebtedness.

 

BofA Securities, Inc., HSBC Securities (USA) Inc., Mizuho Securities USA LLC
and Santander US Capital Markets LLC acted as joint book-running managers on
the transaction. In addition, and in line with our commitment to Inclusion
& Diversity, the women-owned firms R. Seelaus & Co., LLC and Tigress
Financial Partners LLC also acted as underwriters on the transaction.

 

The notes will be issued under AstraZeneca's effective shelf registration
statement on Form F-3, which AstraZeneca and AstraZeneca Finance LLC filed
with the SEC on 24 May 2021. The offering is being made solely by means of the
prospectus contained within that shelf registration statement, along with a
prospectus supplement forming part of the effective registration statement,
which investors should read.

 

A copy of the prospectus supplement and accompanying prospectus relating to
the offering can be obtained by contacting BofA Securities, Inc.,
NC1-004-03-43 200 North College Street, 3rd Floor, Charlotte, NC,
28255-0001, Attn: Prospectus Department by telephone at 1-800-294-1322 or by
emailing dg.prospectus_requests@bofa.com
(mailto:dg.prospectus_requests@bofa.com) ; HSBC Securities (USA) Inc., 452
Fifth Avenue, New York, NY 10018, by telephone at 1-866-811-8049; Mizuho
Securities USA LLC, 1271 Avenue of the Americas, New York, NY 10020, by
telephone at 1- 866-271-7403; or Santander US Capital Markets LLC by telephone
at 1-855-403-3636. Readers may also download these documents for free by
visiting the Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system
on the SEC website at www.sec.gov (http://www.sec.gov) .

 

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy the securities described herein, nor shall there be any sale
of these securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.

 

The bond issuance does not impact AstraZeneca's financial guidance for 2023.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODDZGZZZRFGFZZ